Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Desogestrel

FDA-approved product (tablet, oral-21).

Registered studies
50+
Lab records
0
Pathogens at ≥40%
2 of 4

Chemical structure

Chemical structure of Desogestrel
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

No approved indication recorded

ChEMBL records no approved indication for Desogestrel. Its therapeutic class is shown instead.

WHO therapeutic group
Progestogens
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA50.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli32.6% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae22.0% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis45.3% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Desogestrel in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-7.5 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-7.2 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-7.2 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-8.0 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Desogestrel with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • An Ethno-bridging Study of Pergoveris in Healthy Premenopausal Participants of Japanese or Caucasian Origin

    NCT07269327 · start 2025-11-24

    Registered record
    Registry ID
    NCT07269327
    Conditions
    Fertility
    Interventions
    Desogestrel and ethinylestradiol fixed dose combination; Follitropin alfa/lutropin alfa
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2025-11-24
    Completion
    2026-03-09
    Enrolment
    24

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionFertility
    InterventionDesogestrel and ethinylestradiol fixed dose combination; Follitropin alfa/lutropin alfa
    PhasePhase 1
    Registry statusCompleted

  • Combined Oral Contraceptive Pill and Resistance Starch

    NCT06852365 · start 2025-06-10

    Registered record
    Registry ID
    NCT06852365
    Conditions
    Metabolic Syndrome; Polycystic Ovary Syndrome
    Interventions
    wheat dextrin; Oral Contraceptives, Low-Dose; Maltodextrin
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2025-06-10
    Completion
    2028-04
    Enrolment
    100

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMetabolic Syndrome; Polycystic Ovary Syndrome
    Interventionwheat dextrin; Oral Contraceptives, Low-Dose; Maltodextrin
    PhasePhase 2
    Registry statusRecruiting

  • Effect of Elagolix in Symptomatic Endometrioma in Comparison to Combined Oral Contraceptive Pill.

    NCT07763847 · start 2025-04-17

    Registered record
    Registry ID
    NCT07763847
    Conditions
    Endometrioma
    Interventions
    tab Elagolix 150mg; Combined oral contraceptive pill (ethinyl estradiol,30mcg+desogestrel,150mcg) tablet
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2025-04-17
    Completion
    2026-04-16
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionEndometrioma
    Interventiontab Elagolix 150mg; Combined oral contraceptive pill (ethinyl estradiol,30mcg+desogestrel,150mcg) tablet
    PhaseNot applicable
    Registry statusCompleted

  • Effect of Dienogest in Symptomatic Endometrioma in Comparison to Combined Oral Contraceptive Pill.

    NCT07770594 · start 2025-04-17

    Registered record
    Registry ID
    NCT07770594
    Conditions
    Endometrioma
    Interventions
    Tab.Dienogest 2 mg; Combined oral contraceptive pill (ethinyl estradiol,30mcg+desogestrel,150mcg) tablet
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2025-04-17
    Completion
    2026-04-16
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionEndometrioma
    InterventionTab.Dienogest 2 mg; Combined oral contraceptive pill (ethinyl estradiol,30mcg+desogestrel,150mcg) tablet
    PhaseNot applicable
    Registry statusCompleted

  • PPOS (Progestin Primed Ovarian Stimulation) and Corifollitropin Alfa (CFA) Cross-over Study

    NCT06175832 · start 2025-01-27

    Registered record
    Registry ID
    NCT06175832
    Conditions
    Ovarian Stimulation; Quality of Life; Preimplantation Genetic Testing; Fertility Preservation
    Interventions
    Elonva®; Puregon®; Orgalutran®; Gonapeptyl®; Cerazette®
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Recruiting
    Start
    2025-01-27
    Completion
    2027-12-31
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionOvarian Stimulation; Quality of Life; Preimplantation Genetic Testing; Fertility Preservation
    InterventionElonva®; Puregon®; Orgalutran®; Gonapeptyl® +1 more
    PhasePhase 4
    Registry statusRecruiting

  • Oral Contraceptive Pill (OCP) Pharmacogenomics

    NCT06334315 · start 2024-10-29

    Registered record
    Registry ID
    NCT06334315
    Conditions
    Contraception; Pharmacogenomic Drug Interaction
    Interventions
    Desogestrel / Ethinyl Estradiol Pill
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Recruiting
    Start
    2024-10-29
    Completion
    2028-05
    Enrolment
    700

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionContraception; Pharmacogenomic Drug Interaction
    InterventionDesogestrel / Ethinyl Estradiol Pill
    PhasePhase 4
    Registry statusRecruiting

  • Desogestrel Tablets (0.075 mg) Relative to Originator Desogestrel Tablets (0.075 mg)

    NCT06233084 · start 2024-07-16

    Registered record
    Registry ID
    NCT06233084
    Conditions
    Healthy Subjects
    Interventions
    Desogestrel-Test product; Desogestrel-Reference product
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Unknown
    Start
    2024-07-16
    Completion
    2024-10-03
    Enrolment
    32

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy Subjects
    InterventionDesogestrel-Test product; Desogestrel-Reference product
    PhasePhase 1
    Registry statusUnknown

  • Comparison of Two PPOS Models for Pituitary Suppression

    NCT06304220 · start 2024-07

    Registered record
    Registry ID
    NCT06304220
    Conditions
    Infertility, Female; Fertility Disorders
    Interventions
    Cerazet
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Unknown
    Start
    2024-07
    Completion
    2024-12
    Enrolment
    210

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionInfertility, Female; Fertility Disorders
    InterventionCerazet
    PhaseNot applicable
    Registry statusUnknown

  • Comparison of Sequential CFA vs CFA +rFSH for Elective Fertility Preservation.

    NCT06134479 · start 2023-12-18

    Registered record
    Registry ID
    NCT06134479
    Conditions
    Fertility
    Interventions
    150μg CFA (Elonva®) at stimulation day (SD) 1 and 100μg CFA(Elonva®) at SD 5; 150μg CFA (Elonva®) at SD 1 following by rFSH (Puregon®) 200IU daily from SD 8 until the day of the trigger
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2023-12-18
    Completion
    2025-09-09
    Enrolment
    194

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionFertility
    Intervention150μg CFA (Elonva®) at stimulation day (SD) 1 and 100μg CFA(Elonva®) at SD 5; 150μg CFA (Elonva®) at SD 1 following by rFSH (Puregon®) 200IU daily from SD 8 until the day of the trigger
    PhasePhase 3
    Registry statusCompleted

  • Evaluation of Pharmacokinetic Drug-drug Interactions Between Hormonal Contraceptives and Doravirine-containing ART Among Women Living With HIV in South Africa

    NCT04669678 · start 2021-11-17

    Registered record
    Registry ID
    NCT04669678
    Conditions
    HIV Infections; Contraception; Drug-drug Interaction
    Interventions
    Etonogestrel (ETG) implant; Intramuscular depo-medroxyprogesterone acetate (IM DMPA); Sub-cutaneous medroxyprogesterone acetate (SC MPA); Non-hormonal intrauterine device (IUD)
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2021-11-17
    Completion
    2024-02-05
    Enrolment
    110

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infections; Contraception; Drug-drug Interaction
    InterventionEtonogestrel (ETG) implant; Intramuscular depo-medroxyprogesterone acetate (IM DMPA); Sub-cutaneous medroxyprogesterone acetate (SC MPA); Non-hormonal intrauterine device (IUD)
    PhasePhase 4
    Registry statusCompleted

  • Desogestrel-containing COCP Pharmacokinetic Validation Study

    NCT05002738 · start 2021-09-10

    Registered record
    Registry ID
    NCT05002738
    Conditions
    Contraception
    Interventions
    Desogestrel and Ethinyl Estradiol Tablets
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2021-09-10
    Completion
    2022-11-28
    Enrolment
    22

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionContraception
    InterventionDesogestrel and Ethinyl Estradiol Tablets
    PhasePhase 4
    Registry statusCompleted

  • Desogestrel for the Preoperative Treatment of Endometrioma Compared With Placebo

    NCT04941833 · start 2021-06-01

    Registered record
    Registry ID
    NCT04941833
    Conditions
    Endometrioma
    Interventions
    Desogestrel Oral Tablet
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Completed
    Start
    2021-06-01
    Completion
    2022-09-30
    Enrolment
    20

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionEndometrioma
    InterventionDesogestrel Oral Tablet
    PhasePhase 2 / Phase 3
    Registry statusCompleted

  • Desogestrel Versus GnRH Antagonist in IVF/ICSI

    NCT04728659 · start 2020-10-01

    Registered record
    Registry ID
    NCT04728659
    Conditions
    IVF; Infertility
    Interventions
    Desogestrel 0.075 MG; Orgalutran
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2020-10-01
    Completion
    2022-02-28
    Enrolment
    165

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionIVF; Infertility
    InterventionDesogestrel 0.075 MG; Orgalutran
    PhasePhase 4
    Registry statusUnknown

  • New Ovarian Stimulation With Random Start, Use of Progestin Protocol for Oocyte Donors

    NCT03895099 · start 2020-09-04

    Registered record
    Registry ID
    NCT03895099
    Conditions
    Infertility
    Interventions
    Desogestrel early follicular phase; Desogestrel medium follicular phase; Desogestrel ovulatory phase; Desogestrel late follicular phase; Desogestrel luteal phase
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2020-09-04
    Completion
    2023-10-30
    Enrolment
    110

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionInfertility
    InterventionDesogestrel early follicular phase; Desogestrel medium follicular phase; Desogestrel ovulatory phase; Desogestrel late follicular phase +1 more
    PhasePhase 3
    Registry statusCompleted

  • Bioavailability of Desogestrel 0.075 mg Tablets With Regards to Reference Product

    NCT04422028 · start 2020-01-11

    Registered record
    Registry ID
    NCT04422028
    Conditions
    Bioequivalence
    Interventions
    Desogestrel 0.075 MG; Desogestrel 0.075 MG
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2020-01-11
    Completion
    2020-01-28
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBioequivalence
    InterventionDesogestrel 0.075 MG; Desogestrel 0.075 MG
    PhasePhase 1
    Registry statusCompleted